An age-based clopidogrel dosing scheme may be beneficial for pediatric cardiac patients 0-24 months, suggesting dose escalation with age instead of static low dose.
Does an age-based clopidogrel dosing scheme provide better therapeutic effect than a static low dose in pediatric cardiac patients 0-24 months old?
An age-based clopidogrel dosing scheme may be necessary for pediatric cardiac patients 0-24 months old, challenging the current static low-dose recommendation.
Absolute Event Rate: 0% vs 0%
Pediatric cardiac patients may require a gradual escalation of clopidogrel dosing with age, in contrast to the static low dose recommended by the PICOLO trial during the first 24 months of life. An age-based dosing scheme may prove beneficial for this age group. Prospective studies evaluating age-based clopidogrel dosing in this patient population could offer further insight into this relationship.
Anton-Martin et al. (Sun,) reported a other. An age-based clopidogrel dosing scheme may be beneficial for pediatric cardiac patients 0-24 months, suggesting dose escalation with age instead of static low dose.